The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000770369
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
19/05/2026
Date registered
Help: Date registered
26/06/2026
Date last updated
Help: Date last updated
26/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
26/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A study in healthy adult men to assess the safety, tolerability, and pharmacokinetics of single and multiple doses of SCB0020160, including a food effect assessment following a single dose
Scientific title
A First in Human, Randomized, Double blind, Placebo controlled, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, to explore
the food effect of SCB0020160 after Oral Administration in Healthy Adult Male Subjects
Additional trial identifiers [1] 317193 0
SCB0020160-101
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Advanced Cancer 341772 0
Obesity 342207 0
Pulmonary fibrosis 342208 0
Condition category
Condition code
Cancer 337853 337853 0 0
Other cancer types
Diet and Nutrition 337854 337854 0 0
Obesity
Respiratory 337855 337855 0 0
Other respiratory disorders / diseases

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This study is designed to evaluate the safety, tolerability, and pharmacokinetics of SCB0020160 or placebo after single
and multiple oral administrations in healthy adult male subjects. Considering that the objectives of this study are
exploratory in nature, it differs from studies for typical statistical hypothesis testing. It is desirable to proceed with the
number of subjects required empirically within the limits of satisfying the study objectives, rather than based on a
specific formula. Therefore, the total number of subjects in this study was set to 74 in total (target subjects: 8 subjects
per dose group, substitute subjects: 10 subjects in total). Among them, 10 were substitute subjects, and when all 64
subjects (8 per dose group) complete the study, the study can be closed without recruiting/enrolling substitute subjects.

Part A single-dose study (including food effect study): 40 subjects

The study consists of five dose groups.
In Dose Group 1: 8 subjects will receive either SCB0020160 delayed-release capsules at a dose of 50 mg (1 capsule; 6 subjects) or matching placebo (2 subjects).
In Dose Group 2: 8 subjects will receive 100 mg of SCB0020160 (two 50 mg capsules; 6 subjects) or placebo (2 subjects).
In Dose Group 3: 8 subjects will receive 200 mg of SCB0020160 (four 50 mg capsules; 6 subjects) or placebo (2 subjects).
In Dose Group 4 (food-effect group): 8 subjects will receive 400 mg of SCB0020160 (eight 50 mg capsules; 6 subjects) or placebo (2 subjects).
In Dose Group 5: 8 subjects will receive 600 mg of SCB0020160 (twelve 50 mg capsules; 6 subjects) or placebo (2 subjects)

Part B multiple-dose study: 24 subjects

The study includes three dose groups.
In Dose Group 1: a total of 8 subjects will receive either SCB0020160 delayed-release capsules at a dose of 200 mg (four 50 mg capsules; 6 subjects) or matching placebo (four 50 mg capsules; 2 subjects).
In Dose Group 2: 8 subjects will receive 400 mg of SCB0020160 (eight 50 mg capsules; 6 subjects) or placebo (eight 50 mg capsules; 2 subjects).
In Dose Group 3: 8 subjects will receive 600 mg of SCB0020160 (twelve 50 mg capsules; 6 subjects) or placebo (twelve 50 mg capsules; 2 subjects)."

For Part A, initiation of each subsequent dose cohort will be dependent on review of available safety, tolerability and pharmacokinetic data from the preceding cohort and approval by the SRC.
Subjects randomized to placebo in the food-effect cohort will receive matching placebo under the same fed conditions as active-treated subjects.

Subjects in the food-effect cohort will receive study treatment following a high-fat, high-calorie meal (approximately 800–1000 kcal, with approximately 50% of calories derived from fat). Subjects in all other cohorts will receive study treatment following an overnight fast of at least 10 hours.
All dosing will be administered under direct supervision of study personnel during site confinement. Compliance will be assessed through direct observation and investigational product accountability records.

For Part B, initiation will occur following review of available safety, tolerability and pharmacokinetic data from Part A and approval by the Safety Review Committee (SRC).
Subjects in Part B will receive study treatment under fasting conditions consistent with the non-food-effect cohorts in Part A.

Subjects in Part B will receive once-daily dosing for 14 consecutive days.
Compliance will be assessed through direct observation of dosing and investigational product accountability records.
Intervention code [1] 333959 0
Treatment: Drugs
Description of the comparator or control
The placebo capsule contains polyvinyl caprolactam–polyvinyl acetate–polyethylene glycol graft copolymer, low-substituted hydroxypropyl cellulose (L-HPC), hydroxypropyl cellulose (HPC-L), potassium hydrogen carbonate, tromethamine, and magnesium stearate, enclosed in an enteric-coated capsule shell. The placebo does not contain the active ingredient SCB0020160.
Placebo capsules are packaged in high-density polyethylene (HDPE) bottles with polypropylene caps and a silica gel desiccant pouch.
Control group
Placebo

Outcomes
Primary outcome [1] 345305 0
Safety and tolerability after single and multiple doses ofSCB0020160 assessed using AEs, vital signs, 12 Lead ECGs, Physical examination and laboratory parameters
Timepoint [1] 345305 0
AE- Day 1 until end of study participation Vitals- Part A Dose groups 1, 2, 3, and 5- Part A Dose group 4 (Food Effect)- Part B Dose groups 1, 2, and 3- ECG- Part A: Dose groups 1, 2, 3, and 5 Part A Dose group 4 (Food Effect): Part B Dose groups 1, 2, and 3: Physical Examination- Part A Dose groups 1, 2, 3, and 5 Part A Dose group 4 (Food Effect): Part B Dose groups 1, 2, and 3: Laboratory parameters- Part A Dose groups 1, 2, 3, and 5 Part A Dose group 4 (Food Effect)- Part B Dose groups 1, 2, and 3-
Primary outcome [2] 345307 0
Pharmacokinetics (PK) of SCB0020160 following single and multiple doses
Timepoint [2] 345307 0
Pharmacokinetic assessments will be conducted at protocol-defined time points from Day 1 through Day 21, including intensive PK sampling following the first dose and the final dose, and trough PK assessments during the multiple-dose treatment period. Part A: pharmacokinetic evaluation will be conducted pre-dose, at 0.33, 0.67, 1, 2, 3, 4, 6, 8, 10, 12, 24h (Day 2 0h) post-dose, and at Day 2 12h (36h), Day 3 0h, Day 4 0h, Day 5 0h, Day 6 0h, Day 8 0h. Part B: Pharmacokinetic assessments will be performed at protocol-defined time points from Day 1 through Day 21, including intensive PK sampling following the first dose (Day 1) and the final dose (Day 14), as well as trough PK assessments during the multiple-dose treatment period. Part B: pharmacokinetic evaluation will be conducted pre-dose and at the following time points: Day 1 (pre-dose, and at 0.33, 0.67, 1, 2, 3, 4, 6, 8, 10, 12, 24h (Day 2 0h, pre-dose) postdose), Day 3 0h (pre-dose), Day 4 0h (pre-dose), Day 5 0h (pre-dose), Day 6 0h (pre-dose), Day 7 0h (pre-dose), Day 8 0h (pre-dose), Day 9 0h (pre-dose), Day 10 0h (pre-dose), Day 11 0h (pre-dose), Day 12 0h (pre-dose), Day 13 0h (pre-dose), Day 14 (pre-dose, and at 0.33, 0.67, 1, 2, 3, 4, 6, 8, 10, 12h post-dose), Day 15 0h, Day 16 0h, Day 17 0h, Day 18 0h, Day 19 0h, and Day 21 0h.
Secondary outcome [1] 461511 0
Effect of high fat diet on pharmacokinetic of SCB0020160 post single dose
Timepoint [1] 461511 0
Pharmacokinetic assessments for food-effect evaluation will be conducted at protocol-defined time points during both fasting and fed treatment periods from Day 1 through Day 29. Intensive PK sampling will be performed following dosing under fasting conditions and repeated following dosing under fed conditions. PK samples will be collected serially at predefined time points after each dose administration to evaluate the effect of food on the pharmacokinetics of SCB0020160. Part A: pharmacokinetic evaluation will be conducted pre-dose, at 0.33, 0.67, 1, 2, 3, 4, 6, 8, 10, 12, 24h (Day 2 0h) post-dose, and at Day 2 12h (36h), Day 3 0h, Day 4 0h, Day 5 0h, Day 6 0h, Day 8 0h. Part B: pharmacokinetic evaluation will be conducted pre-dose and at the following time points: Day 1 (pre-dose, and at 0.33, 0.67, 1, 2, 3, 4, 6, 8, 10, 12, 24h (Day 2 0h, pre-dose) postdose), Day 3 0h (pre-dose), Day 4 0h (pre-dose), Day 5 0h (pre-dose), Day 6 0h (pre-dose), Day 7 0h (pre-dose), Day 8 0h (pre-dose), Day 9 0h (pre-dose), Day 10 0h (pre-dose), Day 11 0h (pre-dose), Day 12 0h (pre-dose), Day 13 0h (pre-dose), Day 14 (pre-dose, and at 0.33, 0.67, 1, 2, 3, 4, 6, 8, 10, 12h post-dose), Day 15 0h, Day 16 0h, Day 17 0h, Day 18 0h, Day 19 0h, and Day 21 0h.

Eligibility
Key inclusion criteria
1) Healthy adult male volunteers in the opinion of the principal investigator or delegate, aged 18 to 65 years at screening
2) Body weight more than or equal to 45.0 kg at screening, with a body mass index (BMI) of more than or equal to 18.0 kg/m² and less than or equal to 32.0 kg/m²
3) Eligible to participate in the study based on the results of physical examination, clinical
laboratory tests, history taking, and other examinations performed at screening, as determined by the principal investigator or delegate.
4) Has voluntarily decided to participate and provided written or electronic consent to comply with the precautions after receiving a full explanation of the study and fully understanding it.
Minimum age
18 Years
Maximum age
65 Years
Sex
Males
Healthy volunteers
Yes
Key exclusion criteria
1. Has or has ever had any serious medical condition, including diseases of the liver, kidneys, brain or nerves, immune system, lungs, stomach or intestines, hormones, blood, cancer, heart, urinary system, mental health conditions, or problems related to sexual function.

2. Has or has ever had stomach or bowel diseases such as Crohn’s disease or ulcerative colitis or has had surgery on the stomach or intestines (except appendix removal or hernia surgery).

3. Has a history of allergy or sensitivity to the study medicine, similar medicines, or other medicines such as aspirin or antibiotics.

4. Has inherited problems with digestion of sugars, such as galactose intolerance, lactase deficiency, or glucose-galactose malabsorption.

5. Has abnormal vital signs at screening after resting for at least 5 minutes, including:
* Very low or high blood pressure
* Very slow or very fast heart rate

6. Has an abnormal heart rhythm on the ECG test or any heart rhythm problem considered important by the doctor.

7. Has abnormal results in screening blood or urine tests, including:
* Poor kidney function
* Abnormal blood sugar levels
* Abnormal liver enzyme levels
* High cholesterol levels
* High triglyceride levels

8. Drinks large amounts of alcohol regularly or is unable to stop drinking alcohol from 3 days before the first dose until the end of the study.

9. Has a positive alcohol breath test at screening or on the day before dosing.

10. Currently smokes cigarettes (participants who stopped smoking at least 3 months before the study may be eligible).

11. Has a positive urine test for nicotine or tobacco products at screening or on the day before dosing.

12. Has taken prescription medicines or herbal medicines within 2 weeks before the study, or has taken over-the-counter medicines, vitamins, health supplements, or liver supplements within 1 week before the study, or plans to take them during the study (unless allowed by the study doctor).

13. Has taken medicines that strongly affect drug metabolism within 1 month before the study.

14. Has a history of drug or alcohol misuse or has a positive urine test for recreational drugs.

15. Has participated in another clinical trial or received any investigational medicine within 3 months before this study.

16. Has donated blood within the last 2 months, donated blood components within the last 1 month, or received a blood transfusion within the last 1 month.

17. Drinks excessive caffeine regularly or is unable to stop consuming caffeine-containing products such as coffee, tea, soft drinks, energy drinks, or caffeine supplements from 3 days before dosing until the end of the study.

18. Has consumed grapefruit or grapefruit-containing foods or drinks within 3 days before dosing or is unable to avoid them during the study.

19. Has unusual eating habits or is unable to follow the standard meals provided by the study site during the inpatient stay.

20. Has tested positive for infections such as hepatitis B, hepatitis C, HIV, or syphilis.

21. Does not agree to use reliable birth control during the study and for 90 days after the last dose or does not agree to avoid donating sperm or eggs during this period. Acceptable birth control methods include medically approved contraceptive devices, sterilization, confirmed absence of sperm, long-term hormonal contraception with condom use, or complete sexual abstinence.

22. Is considered unsuitable for the study by the study doctor for any other reason, including inability to follow study requirements.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Treatment allocation is concealed through blinded randomization, with identical packaging and labeling of investigational product and placebo. Allocation codes are securely held and only disclosed after database lock or in emergency situations.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
The randomization numbers will be generated by an independent statistician using the SAS version 9.4
In addition, the randomization will be conducted through the designated Interactive Web Response System (IWRS), and all related verifications and procedures will be conducted and managed within the IWRS.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
Intervention assignment
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA

Funding & Sponsors
Funding source category [1] 321775 0
Commercial sector/Industry
Name [1] 321775 0
SCBIO Inc
Country [1] 321775 0
Korea, Republic Of
Primary sponsor type
Commercial sector/Industry
Name
SCBIO Inc
Address
Country
Korea, Republic Of
Secondary sponsor category [1] 324616 0
None
Name [1] 324616 0
Address [1] 324616 0
Country [1] 324616 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320319 0
Bellberry Human Research Ethics Committee A
Ethics committee address [1] 320319 0
Ethics committee country [1] 320319 0
Australia
Date submitted for ethics approval [1] 320319 0
18/03/2026
Approval date [1] 320319 0
23/04/2026
Ethics approval number [1] 320319 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150074 0
Dr Thomas Polasek
Address 150074 0
CMAX Clinical Research Pty Ltd. Ground Floor, 21-24 North Terrace Adelaide South Australia 5000
Country 150074 0
Australia
Phone 150074 0
+61458162715
Fax 150074 0
Email 150074 0
Contact person for public queries
Name 150075 0
Duksu Lee
Address 150075 0
SCBIO Australia Pty Ltd, Suite 903, Level 9, 263-265 Castlereagh Street, Sydney, NSW 2000
Country 150075 0
Australia
Phone 150075 0
+61 419 995 600
Fax 150075 0
Email 150075 0
Contact person for scientific queries
Name 150076 0
Duksu Lee
Address 150076 0
SCBIO Australia Pty Ltd, Suite 903, Level 9, 263-265 Castlereagh Street, Sydney, NSW 2000
Country 150076 0
Australia
Phone 150076 0
+61 419 995 600
Fax 150076 0
Email 150076 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.